Martin Strassnig, M.D., serves as associate director in the Clinical Translational Research Unit at the Charles E. Schmidt College of Medicine. He is also an associate professor of integrated medical science. Strassnig comes from the University of Miami, where he directed clinical services dedicated to treating acute mental illness while conducting clinical trials. His research concentration is in psychopharmacology, and how to improve medical health and cognitive deficits in people with severe and persistent mental illness, particularly schizophrenia and bipolar disorder. Strassnig is excited to bring his expertise to the research unit, where innovative treatment options, such as medical devices and medications, will be studied. “The unit is about 7,000-square-feet and just opened a few months ago,” Strassnig said. “It allows us to be prepared for a variety of clinical investigations and interventions. We will have a lab and see patients in clinical research studies.” The research unit’s staff is now seeing Alzheimer’s patients and people with other forms of dementia. According to Strassnig, they want to expand into treating people with other mental illnesses as well as other medical disciplines. “The plan is to serve as a platform for all FAU medical researchers, not just those in psychiatry,” he said. “We will provide clinical investigative services and staff support to all potential investigators.” After completing medical school in his native Austria, Strassnig came to the Western Psychiatric Institute and Clinic at the University of Pittsburgh where he completed his residency training and continued on as a clinical and research faculty, partially covered by a National Institutes of Health training grant. At FAU, Strassnig hopes to offer cutting-edge interventions that benefit the local community and help the university fulfill its research mission. “We might be able to help improve the quality of care throughout Palm Beach County,” he said. “That would be my long-term goal.”
1999: M.D., University of Graz, Austria
2001: Visiting Research Fellow: University of Pittsburgh Medical Center, USA
2003: Intern, Adult Psychiatry, Ludwig-Maximilians University Munich, Germany
2007: Research Track Resident, Adult Psychiatry, University of Pittsburgh Medical Center
2016 Associate Professor of Integrated Medical Science, Florida Atlantic University, Charles E Schmidt College of Medicine, Department of Integrated Medical Science
2016: Associate Professor of Psychiatry, University of Miami, Miller School of Medicine, Department of Psychiatry, University Health Network
2016: Assistant Professor of Psychiatry, University of Miami, Miller School of Medicine, Department of Psychiatry, University Health Network
2011: Assistant Professor of Psychiatry University of Toronto, Canada, Department of Psychiatry, Centre for Addiction and Mental Health
2009: Assistant Professor of Psychiatry, University of Pittsburgh Medical Center, Department of Psychiatry, Western Psychiatric Institute and Clinic
Strassnig M, Kotov R, Fochtmann L, Bromet E, Harvey PD. Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder. J Psychiatric Res 2017, in submission.
Strassnig M, Kotov R, Cornaccio D, Fochtmann, L, Bromet E, Havey PD. Twenty-year Progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. Bipolar Disorders, 2017 (in press).
Strassnig M., Signorile, J.F., Potiaumpai, M., Romero, M.A., Gonzalez, C., Czaja, S., Harvey, P.D., High velocity circuit resistance training improves cognition, psychiatric symptoms and neuromuscular performance in overweight outpatients with severe mental illness. Psychiatry Research 2015; 229(1-2): 295-301.
Sabbag, S., Prestia, D., Robertson, B., Ruiz, P., Durand, D., Strassnig, M., Harvey, P.D., Absence of bias in clinician ratings of everyday functioning among AfricanAmerican, Hispanic and Caucasian patients with schizophrenia. Psychiatry Research, 2015; 229(1-2): 347-52.
Strassnig, M.T., T. Raykov, C. O'Gorman, C.R. Bowie, S. Sabbag, D. Durand, T.L. Patterson, A. Pinkham, D.L. Penn, P.D. Harvey, Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity, Schizophrenia Research, 165(1):76-82.
Strassnig, M., J. Clarke, S. Mann, G. Remington, R. Ganguli R, Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia, Early Intervention in Psychiatry, doi: 10.1111/eip.12225, 2015 [Epub ahead of print]
Strassnig, M.T., P.D. Harvey, Treatment resistance and other complicating foactors in the management of schizophrenia, CNS Spectrums, 19 suppl 1: 16-23, 2014
Strassnig, M., J. Signorile, C. Gonzalez, P.D. Harvey, Physical Performance and Disability in Schizophrenia, Schizophrenia Research: Cognition, 1(2): 112-121, 2014
Vargas. T., M. Strassnig, S. Sabbag, F. Gould, D. Durand, L. Stone, T.L. Patterson, P.D. Harvey, The course of vocational functioning in patients with schizophrenia: Re-examining social drift, Schizophrenia Research: Cognition, (1)1: e41-e46, 2014
Durand, D., M. Strassnig, S. Sabbag, F. Gould, E.W. Twamley, T.L. Patterson, P.D. Harvey, Factors influencing self-assessment of cognition and functioing in schizophrenia: implications for treatment studies, European Neuropsychoharmacology, 25(2): 185-191, 2015
Current Funded Research
02/17- Acadia ACP 103-34: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia. Role: Site Principal Investigator
05/17- Acadia ACP 103-038: Extension Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Schizophrenia. Role: Site Principal Investigator